Compare Cassava Sciences Inc (FLNA) vs Fox Corp Class A (FOXA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Fox Corp Class A — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Fox Corp Class A trades at $63.88 (market cap $24.97B). The key difference: Fox Corp Class A is far larger — about 633.8× Cassava Sciences Inc's market cap, and Fox Corp Class A pays a 0.93% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Fox Corp Class A for 34 Days on average.
| FLNA | FOXA | |
|---|---|---|
Market Cap | $39.40M | $24.97B |
Volume | 759,018 | 4,070,311 |
Sector | Health | Media |
52-Week High | $4.64 | $76.11 |
52-Week Low | $0.68 | $48.79 |
Typical Hold Time | 37 Days | 34 Days |
Enterprise Value | -$43.28M | $28.33B |
Dividend Yield | — | 0.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
FOXA trades at $62.70, up 1.0% with a bearish technical signal despite strong fundamentals. The company reported robust earnings beats in recent quarters with Q2 2026 EPS of $1.79 beating expectations by 24%. Revenue grew to $16.3B in 2025 with net income margin expanding to 13.88%. The pending $22B Roku acquisition faces extended DOJ review, creating regulatory uncertainty while CEO Lachlan Murdoch recently purchased $10.3M in shares.
FOXA presents a compelling value case with attractive valuation multiples (P/E 16.33, P/S 1.61) and strong profitability (ROE 14.29%). Analyst consensus targets $72.00 with 52% buy ratings, offering 15% upside potential. Key risks include regulatory hurdles for the Roku deal and projected 2026 margin compression. The stock's current technical weakness may provide entry opportunity for fundamental investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →
